Fry, D W <br/><br/>
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  Sep 1998 
 - 12022-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0027-8424 
<br/><br/><label>Standard No.: </label>10.1073/pnas.95.20.12022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--chemistry<br/>Binding Sites--genetics<br/>Cell Line<br/>Cysteine--chemistry<br/>Enzyme Inhibitors--chemistry<br/>ErbB Receptors--antagonists & inhibitors<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Models, Molecular<br/>Mutagenesis, Site-Directed<br/>Neoplasm Transplantation<br/>Neoplasms, Experimental--drug therapy<br/>Protein Conformation<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Quinazolines--chemistry<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Recombinant Fusion Proteins--antagonists & inhibitors<br/>Transplantation, Heterologous<br/>Tumor Cells, Cultured